Sanofi Regeneron Alliance Expansion Adds Four Long-Acting Immunology Antibodies, Including REGN20423, in $1 Billion Upfront Deal
The Sanofi Regeneron Alliance Expansion adds four long-acting, Regeneron-invented immunology antibodies to the Dupixent partnership. Regeneron receives $1 billion upfront, with up to $7 billion more in potential milestones and a 50:50 profit split.
